Apyx Medical

At the Canaccord Growth Conference, Apyx Medical presented its strategy to expand from a single technology to a broader platform for surgical aesthetics, led by the body-contouring system AYON. Management sees incremental demand from GLP-1 drugs, projects revenue of $59–60 million for 2025, and expects the surgical aesthetics segment to grow 20–22%. AYON is in early market rollout (about 30% of sales to first-time customers) and production is to be scaled this quarter; the company signals it is nearing breakeven. Risks remain around operational execution, production scaling, and converting interest into sustainable revenue. » Mere på de.investing.com

A prospective study of 22 patients published in Aesthetic Surgery Journal Open Forum shows that a combined treatment with Avéli and Renuvion improved the appearance of cellulite in up to 81.8% of patients 180 days after a single session. 3D imaging demonstrated measurable reductions in dimple volume, surface area and depth; histological findings showed increased collagen and elastin and signs of tissue remodeling. Apyx Medical reported revenue of $55.9 million over the past twelve months and has a current ratio of 5.8; the stock is currently trading at $3.79 after a 13% decline this week. » Mere på de.investing.com

Apyx Medical reported Q1 2026 revenue of $12.5 million (+32% year‑on‑year) and earnings per share of -$0.05, both well above expectations. The AYON Body Contouring System drove growth in the Surgical Aesthetics segment and gross profit rose 40% versus Q1 2025. Shares rose 7.88% in premarket trading; the company expects positive cash flow by the end of 2027 and is targeting FDA approval of the Power‑Liposuction feature in Q2 2026. » Mere på de.investing.com